Increased expression of SIAH2 in patients receiving primary chemotherapy for locally advanced breast cancer has been shown to be associated with aggressive tumor features, while low levels of SIAH2, or their reduction after primary chemotherapy, were associated with better response to treatment and survival [141]. The gene discussed is SIAH2; the disease is breast carcinoma.